COLORECTAL CANCER SCREENING

Effective Date: June 19, 2017
Date Of Origin: April 16, 2008

Review Date: 4/08, 4/09, 4/10, 4/11, 12/11, 12/12, 12/13, 2/15, 2/16, 2/17
Status: Current

Summary of Changes

Clarifications:

Deletions:

Additions:

Page 3, Section II, Note, language updated to reflect Computed Tomography Colonography (CTC) may be covered when eviCore criteria are met.

I. POLICY/CRITERIA

A. General Preventive Screening for average risk population:

Average risk is defined as no personal history adenomatous polyps, colorectal cancer, or inflammatory bowel disease (Crohn’s Disease and Ulcerative Colitis); no family history of colorectal cancer or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer.

Beginning at age 50, both men and women at average risk for developing colorectal cancer should begin screening as discussed in the Priority Health Preventive Health Care Guidelines.

Preventive testing modalities include:

1. Fecal occult blood test (FOBT) using guaiac-based FOBT (gFOBT) or immunochemical-based FOBT (iFOBT)
2. Flexible sigmoidoscopy
3. Colonoscopy
4. Computed tomography colonography (CTC)*
5. Fecal DNA (Cologuard)

Fecal DNA testing using Cologuard once every 3 years is considered medically necessary for members who meet all the following criteria:

1. Age 50-75
2. Those patients who show no signs or symptoms of colorectal disease including and not limited to lower gastrointestinal pain, blood in stool, positive fecal occult blood test or fecal immunochemical test
3. No prior history of abnormal fecal DNA test
4. Those patients who are at average risk for developing colorectal cancer
   a. no personal history adenomatous polyps colorectal cancer, or inflammatory bowel disease (Crohn’s Disease and Ulcerative Colitis)
b. no family history of colorectal cancer or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer

B. Advanced Screening and Evaluation Guidelines:
The following cancer screening guidelines are adapted from the Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.

1. **Patients with small rectal hyperplastic polyps** should be considered to have normal colonoscopies, and therefore the interval before the subsequent colonoscopy should be 10 years. An exception is patients with a hyperplastic polyposis syndrome. They are at increased risk for adenomas and colorectal cancer and need to be identified for more intensive follow up.

2. **Patients with only one or two small (<1 cm) tubular adenomas with only low-grade dysplasia** should have their next follow-up colonoscopy in 5 to 10 years. The precise timing within this interval should be based on other clinical factors (such as prior colonoscopy findings, family history, and the preferences of the patient and judgment of the physician).

3. **Patients with 3 to 10 adenomas, or any adenoma > 1 cm, or any adenoma with villous features, or high-grade dysplasia** should have their next follow-up colonoscopy in 3 years providing that piecemeal removal has not been done and the adenoma(s) are completely removed. If the follow-up colonoscopy is normal or shows only one or two small tubular adenomas with low-grade dysplasia, then the interval for the subsequent examination should be 5 years.

4. **Patients who have more than 10 adenomas at one examination** should be examined at a shorter (<3 years) interval established by clinical judgment, and the clinician should consider the possibility of an underlying familial syndrome.

5. **Patients with sessile adenomas that are removed piecemeal** should be considered for follow up at short intervals (2 to 6 months) to verify complete removal. Once complete removal has been established, subsequent surveillance needs to be individualized based on the endoscopist’s judgment. Completeness of removal should be based on both endoscopic and pathologic assessments.

6. **More intensive surveillance is indicated when the family history may indicate an inherited colorectal cancer syndrome such as hereditary nonpolyposis colorectal cancer (HNPCC) or Familial Adenomatous Polyposis (FAP).** See the National Comprehensive Cancer Guidelines (NCCN) for specific screening information for these conditions (www.NCCN.org).
C. Non-covered colorectal cancer screening tests:
   1. **Magnetic resonance imaging (MRI) colonography** is considered experimental and investigational for the screening or diagnosis of colorectal cancer, inflammatory bowel disease, or other indications because its value for these indications has not been established.

   2. **Wireless Capsule Endoscopy (WCE)**
      WCE (i.e. PillCam) is accomplished by encasing video, illumination and transmission modules inside a capsule the size of a large vitamin pill. **WCE is NOT** a covered benefit for general screening.

II. **MEDICAL NECESSITY REVIEW**

   - [x] Required for Computed Tomography Colonography (CTC)*
   - [ ] Not Required
   - [ ] Not Applicable

   *Note: eviCore provides prior authorization medical necessity review services on behalf of Priority Health for participating providers. Prior authorization for out-of-network providers must be requested through Priority Health. Computed Tomography Colonography (CTC) may be covered when eviCore criteria are met.*

III. **APPLICATION TO PRODUCTS**

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

- **HMO/EPO:** This policy applies to insured HMO/EPO plans.
- **POS:** This policy applies to insured POS plans.
- **PPO:** This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
- **ASO:** For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
- **INDIVIDUAL:** For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.
- **MEDICARE:** Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.
- **MEDICAID/HEALTHY MICHIGAN PLAN:** For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: [http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html](http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html). If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: [http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html](http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html), the
IV. BACKGROUND

Colorectal cancer (CRC) causes over 57,000 deaths in the United States annually, making it the second most lethal type of cancer. Widespread screening for colorectal cancer could prevent many of these deaths since prognosis improves dramatically with early detection and treatment. Colon cancer prevention should be the primary goal of CRC screening. Tests that are designed to detect both early cancer and adenomatous polyps should be encouraged if resources are available and patients are willing to undergo an invasive test. Existing screening methods include both invasive and non-invasive tests with varying sensitivities and specificities. Commonly used tests include the fecal occult blood test (FOBT), flexible sigmoidoscopy, traditional colonoscopy and virtual colonoscopy.

V. CODING INFORMATION

ICD-10 Codes that support payment of the following CPT/HCPCS procedures as a preventive benefit (not subject to deductible):

- Z12.11 Encounter for screening for malignant neoplasm of colon
- Z12.12 Encounter for screening for malignant neoplasm of rectum
- Z80.0 Family history of malignant neoplasm of digestive organs
- Z83.71 Family history of colonic polyps
- Z85.00 Personal history of malignant neoplasm of unspecified digestive organ
- Z85.01 Personal history of malignant neoplasm of esophagus
- Z85.020 Personal history of malignant carcinoid tumor of stomach
- Z85.028 Personal history of other malignant neoplasm of stomach
- Z85.030 Personal history of malignant carcinoid tumor of large intestine
- Z85.038 Personal history of other malignant neoplasm of large intestine
- Z85.040 Personal history of malignant carcinoid tumor of rectum
- Z85.048 Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus
- Z85.810 Personal history of malignant neoplasm of tongue
- Z85.818 Personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx
- Z85.819 Personal history of malignant neoplasm of unspecified site of lip, oral cavity, and pharynx
- Z86.010 Personal history of colonic polyps
### CPT/HCPCS Procedure Codes

*These codes billed with modifier 33 - Preventive Services or modifier PT - Colorectal cancer screening test; converted to diagnostic test or other procedure will process as a preventive benefit regardless of diagnosis.*

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>45330*</td>
<td>Sigmoidoscopy, flexible; diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)</td>
</tr>
<tr>
<td>45331*</td>
<td>Sigmoidoscopy, flexible; with biopsy, single or multiple</td>
</tr>
<tr>
<td>45333*</td>
<td>Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery</td>
</tr>
<tr>
<td>45334*</td>
<td>Sigmoidoscopy, flexible; with control of bleeding (eg, injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)</td>
</tr>
<tr>
<td>45335*</td>
<td>Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance</td>
</tr>
<tr>
<td>45338*</td>
<td>Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique</td>
</tr>
<tr>
<td>45346*</td>
<td>Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed) (Not covered for Medicaid)</td>
</tr>
<tr>
<td>45378*</td>
<td>Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or without collection of specimen(s) by brushing or washing, with or without colon decompression (separate procedure)</td>
</tr>
<tr>
<td>45380*</td>
<td>Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple</td>
</tr>
<tr>
<td>45381*</td>
<td>Colonoscopy, flexible; with directed submucosal injection(s), any substance</td>
</tr>
<tr>
<td>45382*</td>
<td>Colonoscopy, flexible, proximal to splenic flexure; with control of bleeding (eg, injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)</td>
</tr>
<tr>
<td>45384*</td>
<td>Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery</td>
</tr>
<tr>
<td>45385*</td>
<td>Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique</td>
</tr>
<tr>
<td>45388*</td>
<td>Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed) (Not covered for Medicaid)</td>
</tr>
<tr>
<td>G0104</td>
<td>Colorectal cancer screening; flexible sigmoidoscopy</td>
</tr>
<tr>
<td>G0105</td>
<td>Colorectal cancer screening; colonoscopy on individual at high risk</td>
</tr>
<tr>
<td>G0121</td>
<td>Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk</td>
</tr>
<tr>
<td>81528</td>
<td>Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result</td>
</tr>
</tbody>
</table>
ICD-10 codes that support payment of the following CPT/HCPCS procedures as a preventive benefit in addition to the codes above:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z00.00</td>
<td>Encounter for general adult medical examination without abnormal findings</td>
</tr>
<tr>
<td>Z00.01</td>
<td>Encounter for general adult medical examination with abnormal findings</td>
</tr>
</tbody>
</table>

CPT/HCPCS procedure codes:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>82270</td>
<td>Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided 3 cards or single triple card for consecutive collection)</td>
</tr>
<tr>
<td>82274</td>
<td>Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations</td>
</tr>
<tr>
<td>G0328</td>
<td>Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous determinations (Not covered for Medicaid)</td>
</tr>
</tbody>
</table>

Pre-authorization required:

Note: eviCore provides prior authorization medical necessity review services on behalf of Priority Health for participating providers. Prior authorization for out-of-network providers must be requested through Priority Health. Computed Tomography Colonography (CTC) may be covered when eviCore criteria are met.

74263  Computed tomographic (CT) colonography, screening, including image postprocessing (Not covered for Priority Medicare or Medicaid)

Only this code qualifies for the preventive benefit for plans that cover this service.

VI. REFERENCES


American Cancer Society. Available on the World Wide Web at [http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Virtual_Colonoscopy](http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Virtual_Colonoscopy), Retrieved 1/26/04.


Pineau, B. C. et. al. “Virtual colonoscopy using oral contrast compared with colonoscopy for the detection of patients with colorectal polyps”. Gastroenterology 2003;125:304-31
“Virtual Colonoscopy” HAYES, Inc. February 2008

AMA CPT Copyright Statement:
All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member’s plan in effect as of the date services are rendered. Priority Health’s medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health’s medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan’s ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name “Priority Health” and the term “plan” mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.